0
Clinical Investigations: SURGERY |

Dexamethasone: Benefit and Prejudice for Patients Undergoing On-Pump Coronary Artery Bypass Grafting*: A Study on Myocardial, Pulmonary, Renal, Intestinal, and Hepatic Injury

Aurora M. Morariu, MD; Berthus G. Loef, MD; Leon P. H. J. Aarts, MD, PhD; Gerrit W. Rietman, MD; Gerhard Rakhorst, DVM, PhD; Wim van Oeveren, PhD; Anne H. Epema, MD, PhD
Author and Funding Information

*From the Department of Biomedical Engineering/Artificial Organs (Drs. Morariu, Rakhorst, and Oeveren), Cardiothoracic Intensive Care Unit (Dr. Loef), and Department of Cardiothoracic Anesthesiology (Drs. Aarts, Rietman, and Epema), University Medical Center Groningen, Groningen, the Netherlands.

Correspondence to: Aurora M. Morariu, MD, Department of BioMedical Engineering/Artificial Organs, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands



Chest. 2005;128(4):2677-2687. doi:10.1378/chest.128.4.2677
Text Size: A A A
Published online

Study objectives: Cardiac surgery with cardiopulmonary bypass (CPB) results in perioperative organ damage caused by the systemic inflammatory response syndrome (SIRS) and ischemia/reperfusion injury. Administration of corticosteroids before CPB has been demonstrated to inhibit the activation of the systemic inflammatory response. However, the clinical benefits of corticosteroid therapy are controversial. This study was designed to document the effects of dexamethasone on cytokine release and perioperative myocardial, pulmonary, renal, intestinal, and hepatic damage, as assessed by specific and sensitive biomarkers.

Design and patients: A prospective, double-blind, placebo-controlled, randomized trial for dexamethasone was conducted in 20 patients receiving either dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10) or placebo (n = 10). Different markers were used to assess the SIRS: interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP), and tryptase; and organ damage: heart (plasma heart-type fatty acid binding protein, cardiac troponin I [cTnI], creatine kinase-MB), kidneys (N-acetyl-glucosaminidase [NAG], microalbuminuria), intestine (intestinal-type fatty acid binding protein [I-FABP]/liver-type fatty acid binding protein [L-FABP]), and liver (α-glutathione S-transferase).

Results: Dexamethasone modulated the SIRS with lower proinflammatory (IL-6, IL-8) and higher antiinflammatory (IL-10) IL levels. CRP and tryptase were lower in the dexamethasone group. cTnI values were lower in the dexamethasone group at 6 h in the ICU (p = 0.009). Patients in the dexamethasone group had a longer time to tracheal extubation (18.86 ± 1.13 h vs 15.01 ± 0.99 h, p = 0.02 [mean ± SEM]), with a lower oxygenation index at that time: Pao2/fraction of inspired oxygen ratio, 37.17 ± 1.8 kPa vs 29.95 ± 2.1 kPa (p = 0.009). The postoperative glucose level (10.7 ± 0.6 mmol/L vs 7.4 ± 0.5 mmol/L, p = 0.005) was higher in the dexamethasone group. Serum glucose was independently associated with intestinal injury (urine I-FABP peak, R2 = 42.5%, β = 114.4 ± 31.4, significant at p = 0.002; urine L-FABP peak, R2 = 47.3%, β = 7,714.1 ± 1,920.9, significant at p = 0.001) and renal injury (urine NAG, R2 = 32.1%, β = 0.21 ± 0.07, significant at p = 0.009). Tryptase peaks correlated negatively with peaks of intestinal and renal injury biomarkers.

Conclusion: Even while inhibiting SIRS, dexamethasone treatment offered no protection against transient, subclinical, perioperative abdominal organ damage. Tryptase release could have a preconditioning effect, offering protection against perioperative intestinal and renal damage. Dexamethasone treatment resulted in more pronounced postoperative pulmonary dysfunction, prolonged time to tracheal extubation, and initiated postoperative hyperglycemia in patients undergoing elective on-pump coronary artery bypass graft surgery.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Effect of Ischemic Preconditioning on Myocardial Protection in Coronary Artery Bypass Graft Patients*: Can the Free Radicals Act as a Trigger for Ischemic Preconditioning?
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543